Collegium Pharmaceutical, Inc. (COLL) saw its loss widen to $27.56 million, or $1.02 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $9.52 million, or $0.46 a share.
Revenues for the quarter were $1.30 million. The company has not recorded any revenues for the previous year period. Gross margin for the quarter was at 85.88 percent.
Operating loss for the quarter was $27.58 million, compared with an operating loss of $9.44 million in the previous year period.
"We have made significant progress on the commercial launch of Xtampza ER. Through mid-February, more than 2,400 physicians have prescribed Xtampza ER, including 800 first time prescribers in 2017 alone," stated Michael Heffernan, Collegium's chief executive officer. "With broadened payer coverage and improved pharmacy availability, we are building a solid foundation for a successful commercial launch."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]